kras mutation and glutathion Targeting Mutant Cancers with a Covalent G12C-Specific Inhibitor: Cell Suppression of the KRAS-NRF2 axis
Description
Corcelle-Termeau et al
Both blends are available at PSPeptides with batch-specific COAs
They all signed the consent forms to be enrolled in the study
If you have a medical condition or are taking any medications, consult your doctor or healthcare professional before use
